CHMP Recommends Variation To Pegasys MA


On March 20 2014, the EMA's CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation (MA) for Roche's Pegasys (peginterferon alpha-2a).

The CHMP adopted a change to an indication as follows: 'Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C in patients with compensated liver disease.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Europe, Switzerland